pipette
ESEspañol

CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers

C. Lyon De Ana, R. Menon, S. K. Bhattarai, A. L. Prince, S. Buresh, E. Darrah, J. M. Norman, R. L. Szabady, D. Bobilev, B. Roberts, J. S. Wang, V. Bucci, J. J. Faith, J. L. Silber, K. Honda, B. Olle, D. Davar

PreprintReal-world use

In the authors' words

Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally.

Main resultLimitation the authors admit

Appeared: Wednesday, November 18. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.13.26368051